Evidence map›Paper›PMID 41487580›Full record

ArticleFrontiers in oncology2025

Prognostic factors of patients with intravascular large B cell lymphoma: a multicenter study in China.

Yan Guo, Yi Zhong, Lixia Zhu, Fengping Zhou, Xuanru Lin, Xian Li, Xiufeng Wang, Yan Huang, Sun Wu, Guoqing Lv and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yan GuoDepartment of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Yi ZhongDepartment of Hematology &Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Lixia ZhuDepartment of Hematology &Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Fengping ZhouDepartment of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xuanru LinDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xian LiDepartment of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Xiufeng WangDepartment of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Yan HuangDepartment of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Sun WuDepartment of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Guoqing LvDepartment of Hematology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Jinghang ZhangDepartment of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Yi ZhaoDepartment of Hematology &Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Wenjun WuDepartment of Hematology &Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Xiujin YeDepartment of Hematology &Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Hanjin YangDepartment of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jin ZhangDepartment of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Kang YuDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yun LiangDepartment of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Zhen CaiDepartment of Hematology &Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Jingsong HeDepartment of Hematology &Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravascular large B-cell lymphoma (IVLBCL) is a rare and highly aggressive lymphoma, but current knowledge is still inadequate. We retrospectively analyzed 50 IVLBCL patients from five Chinese tertiary hospitals in China between 2017 and 2024. Hemophagocytic variant (HV) patients showed worse performance status, universal B symptoms, more bone marrow infiltration, higher mortality, pancytopenia, elevated inflammatory markers (CRP, LDH, ferritin), hypoglobulinemia and hypogammaglobulinemia. Among 46 treated patients, CR/CRu rate was 71% (27/38). The 2-year OS was 65.5%, significantly worse in HV vs. classical variant (CV) (43.3% vs. 76.4%,

Indexed as

Chinaclinicopathologicalintravascular large B-cell lymphomapoor prognostictreatment

Identifiers

PMID41487580
PMCPMC12757299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.